InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,926.02
(
1.02%
)
Post# of 252428
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

exwannabe

Send PM Follow Ignore
Followers 89
Posts 17436
Boards Moderated 0
Alias Born 09/06/2006

exwannabe

Re: DewDiligence post# 45602

Monday, 04/23/2007 4:14:48 PM

Monday, April 23, 2007 4:14:48 PM

Post# of 252428
If we're talking short, NRMX?

Seams like they just about announced that the Alzamed trial results will suck (they just unblinded and announced they will have to tweek the stats analysis plan over the next few weeks).

"Neurochem has been advised by its external team of statisticians that adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. "

Am I wrong about my interpretation here? And if not, how is this stock valued over $5?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up